Loading
Everything OnCo dates to 2021: 793 entries, 197 papers, 194 papers listed on people's pages, 134 landmarks and 97 trials reported. Each line links to the record it was read from, so the year is a view of the corpus rather than a second copy of it.
793 dated entries in OnCo fall in 2021: 197 papers, 194 papers listed on people's pages, 134 landmarks, 97 trials reported, 77 approvals, 32 regulatory events, 26 financing rounds, 11 companies founded, 10 guideline changes, 7 technologies, 6 laws and regulations and 2 journals founded.
Of those, 24 to the day, 18 to the month and 751 to the year only. Most of the corpus dates a fact to the year, because that is what the source it was read from gives; regulatory events and the readout calendar are the parts that carry a full date.
Everything on this page is generated from the other records. It holds no fact of its own, and it changes when they do.
The approvals rows on treatment records: region, year and indication.
Adjuvant high-risk node-positive HR+/HER2- early breast cancer
Exon 20; 1L with lazertinib Jan 2025
EGFR exon 20 insertion NSCLC
CML after ≥2 prior TKIs; T315I CML
ALL/LBL with hypersensitivity to E. coli asparaginase (Rylaze)
Untreated metastatic non-small-cell lung cancer with PD-L1 on at least 50 percent of tumour cells or 10 percent of tumour-infiltrating immune cells and no EGFR or ALK alteration.
First-line EGFR exon 19 deletion or L858R NSCLC (AENEAS)
Advanced systemic mastocytosis
Chronic GVHD after failure of ≥2 lines of systemic therapy (age ≥12)
VHL-associated RCC, CNS haemangioblastoma, pNET
Relapsed/refractory B-ALL in adults
ALK-positive advanced non-small-cell lung cancer not previously treated with an ALK inhibitor. TA670, published 27 January 2021 (ALTA-1L), subject to the commercial arrangement.
First-line advanced RCC with nivolumab (CheckMate 9ER)
Paediatric patients ≥1 year
Relapsed ALK-positive ALCL in patients 1-21 years
HR-positive, HER2-negative advanced breast cancer with fulvestrant after endocrine therapy (DAWNA-1)
HER2+ gastric cancer; HER2-expressing urothelial cancer
First-line unresectable hepatocellular carcinoma (ZGDH3)
dMMR recurrent/advanced endometrial cancer; dMMR solid tumours
CLL after ≥2 therapies; FL after ≥2 therapies
BRAF V600E mutation-positive metastatic colorectal cancer after previous systemic treatment, with cetuximab.
Previously treated MSI-H or dMMR advanced solid tumours
Myelofibrosis, JAK-inhibitor-naive or after ruxolitinib
EGFR T790M-positive locally advanced or metastatic NSCLC after EGFR TKI therapy
Companion claims for sotorasib (KRAS G12C) and amivantamab (EGFR exon 20 insertion)
Adjuvant treatment of resected stage II to IIIA EGFR-mutant NSCLC (EVIDENCE)
Relapsed/refractory myeloma after ≥4 lines
PSMA PET imaging in prostate cancer
PSMA PET imaging in prostate cancer (initial staging with suspected metastasis; suspected recurrence)
Previously treated unresectable or metastatic cholangiocarcinoma with an FGFR2 fusion or rearrangement (accelerated approval). Indication withdrawn in 2024
Untreated metastatic non-small-cell lung cancer, with nivolumab and two cycles of platinum doublet chemotherapy: not recommended. TA724, published 8 September 2021.
Previously treated IDH1-mutated cholangiocarcinoma
Advanced RCC with pembrolizumab; endometrial cancer with pembrolizumab
Relapsed/refractory LBCL after ≥2 lines
Relapsed/refractory DLBCL after ≥2 systemic therapies
First-line ALK+ NSCLC
510(k) clearance, mammography lesion detection
EGFR exon 20 insertion NSCLC after platinum. Withdrawn 2023-24
Locally advanced or metastatic PD-L1-positive non-squamous non-small-cell lung cancer after chemotherapy.
Untreated metastatic non-small-cell lung cancer without an EGFR or ALK alteration, with ipilimumab and two cycles of platinum doublet chemotherapy: not recommended.
Chronic myeloid leukaemia (chronic or accelerated phase) with the T315I mutation after prior tyrosine kinase inhibitors
IDH1 companion claim in cholangiocarcinoma (ivosidenib)
510(k) clearance: AI decision support for indeterminate pulmonary nodules
Intraoperative imaging of ovarian cancer lesions in adults
Aid to pathologists in detecting areas suspicious for cancer on prostate needle biopsy slides (De Novo)
Untreated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency.
Untreated metastatic non-squamous non-small-cell lung cancer without an EGFR or ALK alteration, with pemetrexed and platinum chemotherapy.
Locally recurrent unresectable or metastatic TNBC, PD-L1 CPS 10 or more, with chemotherapy, no prior chemotherapy for metastatic disease (KEYNOTE-355).
High-risk early TNBC, neoadjuvant + adjuvant (KEYNOTE-522)
Same
Locally advanced or metastatic cholangiocarcinoma with FGFR2 fusion or rearrangement after systemic therapy; NICE TA722 recommended 25 August 2021 with a commercial arrangement.
Relapsed/refractory classical Hodgkin lymphoma; later NPC, NSCLC
PSMA PET imaging in prostate cancer
Relapsed or refractory large B-cell lymphoma after two or more lines
Polycythaemia vera
Chronic GVHD after failure of 1-2 lines
mTNBC ≥2 lines; HR+ 2023
Unresectable or metastatic TNBC after two or more systemic therapies, at least one for advanced disease (ASCENT); marketing authorisation issued 22 November 2021.
MET exon 14 skipping NSCLC after platinum chemotherapy or unfit for chemotherapy (conditional; later full)
EU brand Nexpovio. Conditional marketing authorisation
EU brand Retsevmo
Symptomatic, inoperable plexiform neurofibromas in NF1, children 3 and over (conditional)
First-line non-squamous NSCLC with pemetrexed and platinum (ORIENT-11); first-line squamous NSCLC with gemcitabine and platinum (ORIENT-12); first-line unresectable hepatocellular...
Locally advanced unresectable or metastatic malignant PEComa
KRAS G12C NSCLC, previously treated (accelerated)
First-line metastatic squamous and non-squamous NSCLC with platinum chemotherapy (GEMSTONE-302)
EU brand Minjuvi. Conditional marketing authorisation
Metastatic NSCLC with MET exon 14 skipping alterations
Recurrent/metastatic cervical cancer after chemotherapy (full 2024)
Relapsed/refractory advanced RCC after ≥2 prior systemic therapies
To decrease chemotherapy-induced myelosuppression in adults receiving platinum-etoposide or topotecan for extensive-stage small cell lung cancer
Relapsed or refractory adult T-cell leukaemia-lymphoma (HBI-8000)
Relapsed marginal zone lymphoma and follicular lymphoma. Withdrawn 2022
Recurrent or metastatic breast cancer after anthracycline and taxane, with capecitabine
Companion diagnostic for dostarlimab in dMMR endometrial cancer
Companion diagnostic for adjuvant atezolizumab in PD-L1 TC ≥1% resected NSCLC
Relapsed or refractory classical Hodgkin lymphoma after two or more lines of therapy
The regulatory events on treatment records: designations, filings, decisions, label changes and withdrawals, most of them carrying a full date.
HER2+ gastric/GEJ adenocarcinoma (DESTINY-Gastric01)
Breakthrough Therapy designation
Advanced basal cell carcinoma after hedgehog inhibitor
First-line PD-L1 ≥50% NSCLC (EMPOWER-Lung 1)
First-line ALK+ NSCLC (CROWN); full approval
Relapsed/refractory follicular lymphoma (ZUMA-5)
Paediatric expansion
Full approval in metastatic TNBC (ASCENT); accelerated approval in urothelial cancer
Accelerated approval, dMMR recurrent/advanced endometrial cancer after platinum
Accelerated approval, relapsed/refractory DLBCL after ≥2 lines (LOTIS-2)
Accelerated approval, EGFR exon 20 insertion NSCLC after platinum
PSMA PET imaging in prostate cancer: first 18F PSMA agent
Accelerated approval, KRAS G12C NSCLC after ≥1 therapy: first KRAS inhibitor
Breakthrough Therapy designation
Conditional approval, HER2+ gastric cancer after ≥2 lines
Launched as a laboratory-developed test
Breakthrough Therapy designation
Breakthrough Therapy designation
Full approval and cisplatin-ineligible expansion (EV-301)
Full approval, pMMR endometrial cancer (KEYNOTE-775)
High-risk early TNBC, neoadjuvant and adjuvant (KEYNOTE-522)
Genentech withdrew the US TNBC indication after the confirmatory IMpassion131 trial (paclitaxel partner) showed no progression-free or overall survival benefit and the FDA's accele...
VHL disease-associated RCC, CNS haemangioblastoma, pNET: first HIF-2α inhibitor
dMMR solid tumours (tumour-agnostic, accelerated)
TNBC indication withdrawn after IMpassion131
Accelerated approval, recurrent or metastatic cervical cancer after chemotherapy (innovaTV 204)
Medicare coverage for immunotherapy response monitoring, pan-cancer
Adjuvant high-risk node-positive HR+/HER2- early breast cancer, Ki-67 ≥20% (monarchE)
Adjuvant NSCLC, PD-L1 ≥1% (IMpower010)
EMA approval, pretreated metastatic TNBC
Breakthrough Therapy designation, EGFR-mutant NSCLC after TKI and platinum
HER2-expressing urothelial cancer after platinum
The statutes, regulations, guidance and court rulings in the law index, dated to the year the instrument was made.
European Union, regulation.
France, statute.
United Kingdom, scheme.
United Kingdom, statute.
China, statute.
United States, statute.
The dated NCCN and ESMO versions in the guideline history, with the rows each one added, removed or recategorised.
1 row recategorised, 1 row added. Anchored to Annals of Oncology publication, 2021.
2 rows added. Anchored to Annals of Oncology publication, 2021.
2 rows added. Anchored to FDA approvals of trastuzumab deruxtecan for HER2-positive gastric cancer (January 2021, DESTINY-Gastric01) and nivolumab with chemotherapy (April 2021, Ch...
2 rows added. Anchored to FDA approvals of dostarlimab for dMMR recurrent disease (April 2021, GARNET) and full approval of lenvatinib plus pembrolizumab (July 2021, KEYNOTE-775).
1 row added, 1 row removed. Anchored to FDA approval of neoadjuvant and adjuvant pembrolizumab (July 2021, KEYNOTE-522); withdrawal of the atezolizumab TNBC indication (August 2021...
4 rows added. Anchored to FDA approvals of adjuvant osimertinib (December 2020, ADAURA), sotorasib and amivantamab (May 2021), adjuvant atezolizumab (October 2021, IMpower010).
1 row added. Anchored to FDA approval of adjuvant abemaciclib, October 2021 (monarchE).
2 rows added. Anchored to FDA accelerated approval of tisotumab vedotin (September 2021) and approval of pembrolizumab with chemotherapy for PD-L1 CPS 1 or above (October 2021, KEY...
1 row recategorised, 1 row added. Anchored to Annals of Oncology publication, November 2021.
2 rows added. Anchored to FDA approvals of nivolumab plus cabozantinib (January 2021, CheckMate 9ER), pembrolizumab plus lenvatinib (August 2021, CLEAR) and adjuvant pembrolizumab...
The year reported on trial records, with the headline result the record gives.
Blinatumomab consolidation gave two-year disease-free survival of 54.4 percent against 39.0 percent with chemotherapy in high- and intermediate-risk relapse (not statistically sign...
Objective response 39% (independent review), durable, enriched in TSC2-mutant tumours; FDA approval November 2021.
ORR 71% (naive MTC), 89% (RET-fusion thyroid).
Very high three-year invasive disease-free survival with one year of trastuzumab emtansine in stage I disease, but clinically relevant toxicity was not lower than with paclitaxel p...
OS HR 0.97, not significant.
EFS HR 1.07 (negative).
Three-year overall survival 47.9 percent with a donor and reduced-intensity transplant against 26.6 percent without a donor (p 0.0001); leukaemia-free survival 35.8 against 20.6 pe...
ORR 31.4%; median DOR 36.5 months (5-year analysis).
PFS 11.3 vs 8.3 months, HR 0.60.
Median progression-free survival 9.7 vs 6.9 months (hazard ratio 0.54).
CR 55%; uMRD 77%; 4-year PFS ~79%.
ORR 98%; ~33% progression-free at 5 years without maintenance.
Median overall survival 11.6 months overall; 17.3 months with RAS and BRAF wild-type plasma against 10.4 months with mutated plasma (hazard ratio 0.49).
Objective response by independent central review in 26 of 84 patients (31 per cent, 95 per cent confidence interval 21 to 42) with five complete responses; grade 3 or 4 treatment-e...
DFS HR 0.70; OS HR 0.83 (ITT), median 75 vs 50.1 months.
DFS 22.4 vs 11.0 months (HR 0.69); OS 51.7 vs 35.3 months (HR 0.85, NS).
PD-L1 ≥1%: OS 15.4 vs 9.1 months (nivo + chemo, HR 0.54); 13.7 vs 9.1 months (nivo + ipi, HR 0.64).
Amivantamab produced durable responses in EGFR exon 20 insertion non-small-cell lung cancer after platinum chemotherapy; accelerated approval in May 2021.
PFS 23.9 vs 9.2 months (HR 0.39); OS HR 0.79.
Temozolomide alone gave shorter progression-free survival than radiotherapy-containing treatment in 1p/19q-codeleted glioma; the redesigned comparison of radiotherapy with temozolo...
Involved-field boost non-inferior (5-year EFS 82.5% vs 80.5%); 18 Gy CSI inferior to 23.4 Gy (71.4% vs 82.9%).
Carboplatin radiosensitisation improved event-free and overall survival in group 3 high-risk medulloblastoma; isotretinoin maintenance was stopped for futility.
PFS 15.7 vs 7.2 months, HR 0.42.
PFS HR 0.33; OS HR 0.64.
Confirmed objective response 45.3 percent in HER2-positive disease; interstitial lung disease in 6 percent, two deaths.
2-year OS 71.8% vs 51.5%.
Closed for futility: platinum not superior or non-inferior to capecitabine for iDFS in basal-like residual TNBC (primary hazard ratio not indexed).
PFS HR 0.55 in ESR1-mutant.
OS 12.0 vs 8.5 months (HR 0.69).
Median overall survival not reached vs 14.2 months (hazard ratio 0.57) in PD-L1 50% or more; 26.1 vs 13.3 months in the three-year update; median progression-free survival 8.2 vs 5...
OS 15.3 vs 12.0 months, HR 0.70.
Median progression-free survival 25.8 vs 12.7 months (hazard ratio 0.51, blinded independent review, intent-to-treat); intracranial response 63.6% vs 21.1% in patients with target...
Overall response rate 75 percent and complete remission rate 36 percent in 53 evaluable patients with advanced systemic mastocytosis; maximum tolerated dose not reached; recommende...
6 of 15 patients with clinical benefit (3 objective responses).
FOCUS4-C: adavosertib improved progression-free survival in RAS and TP53 co-mutated tumours (hazard ratio 0.35).
PFS HR 0.216; OS HR 0.487 (4-year).
Efficacy against persistent HPV 16/18 infection: 95.4% (1 dose), 93.1% (2 doses), 93.3% (3 doses) at 10 years.
OS 21.7 vs 16.0 months; HR 0.51.
PFS HR 0.52; OS HR 0.63.
OS in CPS 10 or more 12.7 vs 11.6 months (HR 0.78, p 0.057); CPS 1 or more 10.7 vs 10.2 (HR 0.86); all patients 9.9 vs 10.8 (HR 0.97). Negative.
DFS HR 0.72; OS HR 0.62.
RFS and DMFS improved; 5-year benefit sustained (ESMO 2025).
OS 18.3 vs 11.4 months (HR 0.62).
Higher response rate and longer progression-free survival with pembrolizumab added to trastuzumab and chemotherapy, with benefit concentrated in PD-L1-positive tumours; accelerated...
OS 26.4 vs 16.8 months (HR 0.63), all comers.
ORR 48%, CR 24%.
Haematocrit at or below 45% without progression at 12 months: 84% vs 60%.
Postoperative mediastinal radiotherapy did not improve three-year disease-free survival in completely resected N2 disease; mediastinal relapse fell but cardiopulmonary toxicity ros...
Nivolumab plus ipilimumab did not improve survival over nivolumab alone; the trial closed for futility.
Surgical conversion 35.9 percent with continued nab-paclitaxel plus gemcitabine against 43.9 percent with sequential FOLFIRINOX (odds ratio 0.72; p 0.38); median overall survival 1...
BICR PFS 7.1 vs 1.4 months, HR 0.56 (0.39 to 0.81), p=0.0019; re-read PFS 4.2 vs 1.7 months, HR 0.61 (0.44 to 0.86).
iDFS HR 0.58; OS HR 0.72.
OS HR 0.57; PFS HR 0.56.
5-year OS 72% vs 71%; no benefit.
Six-month progression-free survival 47.1 percent (six months of FOLFIRINOX), 42.9 percent (four months then fluorouracil maintenance) and 34.1 percent (alternating gemcitabine and...
Cabozantinib lengthened progression-free survival compared with sunitinib in metastatic papillary renal cell carcinoma; the crizotinib and savolitinib arms closed for futility.
Transdermal oestradiol suppressed testosterone as well as a luteinising hormone-releasing hormone agonist with no difference in time to first cardiovascular event (hazard ratio 1.1...
OS HR 0.82 in the overall population and HR 0.75 in the ADT plus docetaxel population; HR 0.72 in high-volume disease.
One year of palbociclib added to endocrine therapy did not improve invasive disease-free survival.
2-year PFS 76.7% vs 70.2%, HR 0.73; 5-year OS HR 0.85 (NS).
5-year biochemical failure-free survival 95% (whole pelvis) vs 81.2% (prostate only).
3-year disease-free survival 76% vs 69% (hazard ratio 0.69); pathological complete response 28% vs 12%.
Median overall survival 41.7 against 41.2 months (hazard ratio 1.00); more late grade 3 or worse complications with HIPEC.
Per-patient sensitivity 0.40 (95% CI 0.34 to 0.46) and specificity 0.95 (0.92 to 0.97) for pelvic nodal metastasis against histopathology in the 277-man surgery cohort; positive pr...
ORR 75.9%, CR 51.7%.
Median overall survival 9.7 months with ibrutinib plus nab-paclitaxel and gemcitabine against 10.8 months with placebo (p 0.3225); progression-free survival 5.3 against 6.0 months...
Best overall response 74% (200 mg once daily) and 77% (200 mg twice daily); the FDA analysis of the once-daily dose found 75% through cycle 7 day 1.
Closed early for slow recruitment; the underpowered comparison favoured lanreotide over placebo for progression-free survival.
IMpower010: adjuvant atezolizumab after platinum chemotherapy improved disease-free survival in resected stage II to IIIA non-small-cell lung cancer, most in tumours with PD-L1 on...
Progression-free survival hazard ratio 0.50 with vemurafenib added; response 17 against 4 percent.
Two-year overall survival 47 percent with perioperative modified FOLFIRINOX and 48 percent with perioperative gemcitabine plus nab-paclitaxel; neither exceeded the 40 percent histo...
5-year DFS 82.8% vs 73.0% (HR 0.64, p 0.03); 10-year DFS 78.1% vs 66.6% (HR 0.61); 10-year OS 82.4% vs 73.7% (HR 0.67, p 0.058).
PSA50 66% vs 37%; OS HR 0.97.
Relapse-free survival hazard ratio 1.13 for three against six months, crossing the non-inferiority limit; no overall survival difference.
TPEx did not improve overall survival over EXTREME, but gave similar survival with a shorter schedule and less toxicity.
Confirmed objective response 30 percent in tissue-positive and 28 percent in ctDNA-positive patients, against 0 percent in a matched real-world reference group.
Primary overall survival endpoint not met.
No significant reduction in ovarian cancer mortality.
42 cancers in 1,994 people scanned, 85.7 percent at stage 1 or 2; lung cancer mortality relative rate 0.65 (0.41 to 1.02) at a median 7.3 years, and 0.84 (0.76 to 0.92) pooled with...
Serum phosphorus rose from 0.52 mmol/L at baseline to 0.82 mmol/L at week 144 (p<0.0001); 33% of baseline fractures or pseudofractures fully healed and 13% partially healed by week...
OS HR 0.62.
Surgical downstaging in 44 of 55 patients (80 per cent, 95 per cent confidence interval 67 to 90) with 27 complete responses, an objective response rate of 71 per cent, and recurre...
OS 12.1 vs 10.3 months, HR 0.83.
High objective and complete response rates in relapsed follicular lymphoma with durable remissions; accelerated approval in March 2021.
EFS HR 0.40; OS HR 0.73; 4-year OS 54.6% vs 46.0%.
The publication year on key paper records.
Hofman MS, Emmett L, Sandhu S, et al. The Lancet.
Bible KC, Kebebew E, Brierley J, et al. Thyroid.
Heuser M, Freeman SD, Ossenkoppele GJ, et al. Blood.
Kalinsky K, Barlow WE, Gralow JR, et al. New England Journal of Medicine.
Piccart M, van 't Veer LJ, Poncet C, et al. The Lancet Oncology.
Mansoori S, Fryknäs M, Alvfors C, Loskog A, Larsson R, Nygren P. Scientific Reports.
Adusumilli PS, Zauderer MG, Rivière I, et al. Cancer Discovery.
Brown PA, Ji L, Xu X, et al. JAMA.
Byrd JC, Byrd JC, Hillmen P, et al. Journal of Clinical Oncology.
Michalski JM, Janss AJ, Vezina LG, et al. Journal of Clinical Oncology.
Leary SES, Packer RJ, Li Y, et al. JAMA Oncology.
Stacchiotti S, Simeone N, Lo Vullo S, et al. Cancer.
Felip E, Altorki N, Zhou C, et al. The Lancet.
Eggermont AMM, Blank CU, Mandalà M, et al. The Lancet Oncology.
Rumgay H, Shield K, Charvat H, et al. Lancet Oncology.
André F, Ciruelos EM, Juric D, et al. Annals of Oncology.
Jumper J, Evans R, Pritzel A, et al. Nature.
Park K, Haura EB, Leighl NB, et al. Journal of Clinical Oncology.
Wagner AJ, Ravi V, Riedel RF, et al. Journal of Clinical Oncology.
Moore E, Silverman BG, Fishler Y, Ben-Adiva E, Davidov O, Dichtiar R, Edri H, Zatlawi M, Keinan-Boker L. Israel Medical Association Journal.
McGuinness JE, Kalinsky K. Expert opinion on biological therapy.
Yamazaki CM, Yamaguchi A, Anami Y, et al. Nature Communications.
Saad F, Efstathiou E, Attard G, et al. The Lancet Oncology.
Gainor JF, Curigliano G, Kim DW, et al. The Lancet Oncology.
Bardia A, Hurvitz SA, Tolaney SM, et al. New England Journal of Medicine.
Schneider BJ, Naidoo J, Santomasso BD, et al. Journal of Clinical Oncology.
Jensen K, Konnick EQ, Schweizer MT, et al. JAMA Oncology.
Raghav K, Liu S, Overman MJ, et al. Cancer Discovery.
Cutler C, Lee SJ, Arai S, et al. Blood.
Jonasch E, Donskov F, Iliopoulos O, et al. New England Journal of Medicine.
Levin M. Cell.
Bardia A, Tolaney SM, Punie K, et al. Annals of Oncology.
Nakamura R, Saber W, Martens MJ, et al. Journal of Clinical Oncology.
Strauss SJ, Frezza AM, Abecassis N, et al. Annals of Oncology.
Hirose K, Konno A, Hiratsuka J, et al. Radiotherapy and Oncology.
Camidge DR, Kim HR, Ahn MJ, et al. Journal of Thoracic Oncology.
Jan de Beur SM, Miller PD, Weber TJ, et al. Journal of Bone and Mineral Research.
Sarnaik AA, Hamid O, Khushalani NI, et al. Journal of Clinical Oncology.
Zhou C, Chen G, Huang Y, et al. The Lancet. Respiratory medicine.
Adams RA, Fisher DJ, Graham J, et al. Journal of Clinical Oncology.
Yang Y, Qu S, Li J, et al. The Lancet Oncology.
Berdeja JG, Madduri D, Usmani SZ, et al. The Lancet.
Stratigos AJ, Sekulic A, Peris K, et al. The Lancet Oncology.
Sezer A, Kilickap S, Gümüş M, et al. The Lancet.
Kelly RJ, Ajani JA, Kuzdzal J, et al. New England Journal of Medicine.
Janjigian YY, Shitara K, Moehler M, et al. The Lancet.
Baas P, Scherpereel A, Nowak AK, et al. The Lancet.
Pérez-García JM, Gebhart G, Ruiz Borrego M, et al. The Lancet Oncology.
Magbanua MJM, Swigart LB, Wu HT, et al. Annals of Oncology.
Nakamura Y, Okamoto W, Kato T, et al. Nature Medicine.
Motzer R, Alekseev B, Rha SY, et al. New England Journal of Medicine.
Antill Y, Kok PS, Robledo K, et al. Journal for ImmunoTherapy of Cancer.
Denkert C, Seither F, Schneeweiss A, et al. The Lancet Oncology.
Larson KL, Huang B, Weiss HL, et al. JCO Precision Oncology.
Nagino M, Hirano S, Yoshitomi H, et al. Journal of Hepato-Biliary-Pancreatic Sciences.
Klein EA, Richards D, Cohn A, et al. Annals of Oncology.
Schettini F, Chic N, Brasó-Maristany F, et al. NPJ Breast Cancer.
Kakiuchi N, Ogawa S. Nature Reviews Cancer.
Barchuk A, Tursun-Zade R, Belayev A, et al. Acta oncologica.
Luchini C, Brosens LAA, Wood LD, et al. Gut.
Jochelson MS, Lobbes MBI. Radiology.
Chen YP, Ismaila N, Chua MLK, et al. Journal of Clinical Oncology.
Quénet F, Elias D, Roca L, et al. The Lancet Oncology.
Xu B, Zhang Q, Zhang P, et al. Nature Medicine.
Harter P, Sehouli J, Vergote I, et al. New England Journal of Medicine.
Hope TA, Eiber M, Armstrong WR, et al. JAMA Oncology.
Spencer CN, McQuade JL, Gopalakrishnan V, et al. Science.
Goldman JW, Dvorkin M, Chen Y, et al. The Lancet Oncology.
Goldbrunner R, Stavrinou P, Jenkinson MD, et al. Neuro-Oncology.
Weller M, van den Bent M, Preusser M, et al. Nature Reviews Clinical Oncology.
McNeil JJ, Gibbs P, Orchard SG, et al. JNCI: Journal of the National Cancer Institute.
Qian DC, Kleber T, Brammer B, et al. The Lancet Oncology.
Avsec Ž, Agarwal V, Visentin D, et al. Nature methods.
Westin JR, Kersten MJ, Salles G, et al. American journal of hematology.
Tabernero J, Grothey A, Van Cutsem E, et al. Journal of Clinical Oncology.
Falcaro M, Castañon A, Ndlela B, et al. The Lancet.
Kurtz DM, Soo J, Co Ting Keh L, et al. Nature Biotechnology.
Horn L, Wang Z, Wu G, et al. JAMA Oncology.
Stacchiotti S, Miah AB, Frezza AM, et al. ESMO Open.
Concin N, Matias-Guiu X, Vergote I, et al. International journal of gynecological cancer.
Gennari A, André F, Barrios CH, et al. Annals of Oncology.
Rao S, Guren MG, Khan K, et al. Annals of Oncology.
Muscaritoli M, Arends J, Bachmann P, et al. Clinical nutrition (Edinburgh, Scotland).
Rahib L, Wehner MR, Matrisian LM, Nead KT. JAMA Network Open.
Danchev V, Min Y, Borghi J, et al. JAMA network open.
DeAngelo DJ, Radia DH, George TI, et al. Nature Medicine.
Shah M, Rahman A, Theoret MR, Pazdur R. New England Journal of Medicine.
Davar D, Dzutsev AK, McCulloch JA, et al. Science.
Baruch EN, Youngster I, Ben-Betzalel G, et al. Science.
Ferlay J, Colombet M, Soerjomataram I, et al. International Journal of Cancer.
Ngan HYS, Seckl MJ, Berkowitz RS, et al. International Journal of Gynecology & Obstetrics.
Reck M, Rodríguez-Abreu D, Robinson AG, et al. Journal of Clinical Oncology.
Hoskin P, Popova B, Schofield O, et al. The Lancet Oncology.
Shah N, Eyre TA, Tucker D, et al. British journal of haematology.
Mohile SG, Mohamed MR, Xu H, et al. The Lancet.
Tukachinsky H, Madison RW, Chung JH, et al. Clinical Cancer Research.
Zhang T, Joubert P, Ansari-Pour N, et al. Nature Genetics.
Lin J, Peng X, Dong K, et al. Nature Communications.
Oonk MHM, Slomovitz B, Baldwin PJW, et al. Journal of Clinical Oncology.
Llovet JM, Kelley RK, Villanueva A, et al. Nature reviews. Disease primers.
Wu E, Wu K, Daneshjou R, et al. Nature Medicine.
Gillessen S, Sauvé N, Collette L, et al. Journal of Clinical Oncology.
Patil PA, Lombardo K, Cao W. Applied Immunohistochemistry and Molecular Morphology.
Ackerman SE, Pearson CI, Gregorio JD, et al. Nature Cancer.
Fernández de Larrea C, Kyle R, Rosiñol L, et al. Blood cancer journal.
Seligmann JF, Fisher DJ, Brown LC, et al. Journal of Clinical Oncology.
Nepal C, Zhu B, O'Rourke CJ, et al. Journal of Hepatology.
Orecchia R, Veronesi U, Maisonneuve P, et al. The Lancet Oncology.
Sweeney C, Bracarda S, Sternberg CN, et al. Lancet.
Draganov D, Han Z, Rana A, Bennett N, Irvine DJ, Lee PP. npj Breast Cancer.
Tang M, Hu X, Wang Y, et al. Pharmacological Research.
Mai HQ, Chen QY, Chen D, et al. Nature Medicine.
Balar AV, Kamat AM, Kulkarni GS, et al. The Lancet Oncology.
Kuruvilla J, Ramchandren R, Santoro A, et al. The Lancet Oncology.
Choueiri TK, Tomczak P, Park SH, et al. New England Journal of Medicine.
Sun JM, Shen L, Shah MA, et al. The Lancet.
Colombo N, Dubot C, Lorusso D, et al. New England Journal of Medicine.
Fahrmann JF, Schmidt CM, Mao X, et al. Gastroenterology.
Yoo C, Kim KP, Jeong JH, et al. The Lancet Oncology.
Tawbi HA, Forsyth PA, Hodi FS, et al. The Lancet Oncology.
Opat S, Tedeschi A, Linton K, et al. Clinical Cancer Research.
Vanhersecke L, Brunet M, Guégan JP, et al. Nature Cancer.
Authors not listed. Nature methods.
Tjulandin S, Demidov L, Moiseyenko V, et al. European Journal of Cancer.
Ren XY, Song Y, Wang J, et al. Frontiers in Oncology.
Lehmann BD, Colaprico A, Silva TC, et al. Nature Communications.
Wagner MJ, Othus M, Patel SP, et al. Journal for ImmunoTherapy of Cancer.
Bradt J, Dileo C, Myers-Coffman K, et al. The Cochrane database of systematic reviews.
DiNardo CD, Stein AS, Stein EM, et al. Journal of Clinical Oncology.
Boorjian SA, Alemozaffar M, Konety BR, et al. The Lancet Oncology.
Bossi P, Chan AT, Licitra L, et al. Annals of Oncology.
Conroy T, Bosset JF, Etienne PL, et al. The Lancet Oncology.
Korde LA, Somerfield MR, Carey LA, et al. Journal of Clinical Oncology.
Gettinger SN, Redman MW, Bazhenova L, et al. JAMA Oncology.
Lee YA, Lee H, Im SW, et al. Journal of Clinical Investigation.
Sedrak MS, Freedman RA, Cohen HJ, et al. CA: A Cancer Journal for Clinicians.
Tutt ANJ, Garber JE, Kaufman B, et al. New England Journal of Medicine.
Menon U, Gentry-Maharaj A, Burnell M, et al. The Lancet.
Nathan P, Hassel JC, Rutkowski P, et al. New England Journal of Medicine.
Loibl S, Marmé F, Martin M, et al. Journal of Clinical Oncology.
Mayer EL, Dueck AC, Martin M, et al. The Lancet Oncology.
Tempero MA, Malafa MP, Al-Hawary M, et al. Journal of the National Comprehensive Cancer Network.
Bien E, Roganovic J, Krawczyk MA, et al. Pediatric Blood & Cancer.
Pal SK, Tangen C, Thompson IM, et al. The Lancet.
Gotlib J, Reiter A, Radia DH, et al. Nature Medicine.
Gay CM, Stewart CA, Park EM, et al. Cancer Cell.
Tabrizian P, Florman SS, Schwartz ME. American journal of transplantation.
Rugo HS, Loi S, Adams S, et al. Journal of the National Cancer Institute.
Cooper BM, Iegre J, O' Donovan DH, et al. Chemical Society reviews.
Javle M, Borad MJ, Azad NS, et al. The Lancet Oncology.
Reiss KA, Mick R, O'Hara MH, et al. Journal of Clinical Oncology.
Moore KN, Oza AM, Colombo N, et al. Annals of Oncology.
Sheikh M, Mukeriya A, Shangina O, et al. Annals of Internal Medicine.
Miles D, Gligorov J, André F, et al. Annals of Oncology.
Kang H, Choi YS, Suh SW, et al. Journal of Clinical Medicine.
Albrecht T, Brinkmann F, Albrecht M, et al. Cancers.
Murthy V, Maitre P, Kannan S, et al. Journal of Clinical Oncology.
Nayak L, Molinaro AM, Peters K, et al. Clinical Cancer Research.
Gonda TA, Everett JN, Wallace M, Simeone DM, PRECEDE Consortium. Gastroenterology.
Ying Z, Yang H, Guo Y, et al. Cancer medicine.
Errington TM, Mathur M, Soderberg CK, et al. eLife.
Adams E, Wildiers H, Neven P, et al. ESMO Open.
Koelsche C, Schrimpf D, Stichel D, et al. Nature Communications.
US Preventive Services Task Force, Krist AH, Davidson KW, et al. JAMA.
Lamarca A, Palmer DH, Wasan HS, et al. The Lancet Oncology.
Bahadoer RR, Dijkstra EA, van Etten B, et al. The Lancet Oncology.
Siegel RL, Miller KD, Fuchs HE, Jemal A. CA: A Cancer Journal for Clinicians.
Ren Z, Xu J, Bai Y, et al. The Lancet Oncology.
Rudin CM, Brambilla E, Faivre-Finn C, et al. Nature reviews. Disease primers.
Gronchi A, Miah AB, Dei Tos AP, et al. Annals of Oncology.
Skoulidis F, Li BT, Dy GK, et al. New England Journal of Medicine.
Grunwald BT, Devisme A, Andrieux G, et al. Cell.
Topham JT, Karasinska JM, Lee MKC, et al. Clinical Cancer Research.
Hur J, Otegbeye E, Joh HK, et al. Gut.
Sung H, Ferlay J, Siegel RL, et al. CA: A Cancer Journal for Clinicians.
Zon RT, Kennedy EB, Adelson K, et al. JCO Oncology Practice.
Louis DN, Perry A, Wesseling P, et al. Neuro-Oncology.
Zhang Y, Wushouer H, Han S, et al. BMJ global health.
Ranganathan P, Chinnaswamy G, Sengar M, et al. The Lancet Oncology.
Hu X, Li J, Fu M, et al. Signal transduction and targeted therapy.
Fabbri L, Chakraborty A, Robert C, et al. Nature Reviews Cancer.
Nghiem P, Bhatia S, Lipson EJ, et al. Journal for ImmunoTherapy of Cancer.
Yala A, Mikhael PG, Strand F, et al. Science Translational Medicine.
Guigay J, Aupérin A, Fayette J, et al. The Lancet Oncology.
Conti DV, Darst BF, Moss LC, et al. Nature Genetics.
Langley RE, Gilbert DC, Duong T, et al. The Lancet.
Denmeade SR, Wang H, Agarwal N, et al. Journal of Clinical Oncology.
Siena S, Di Bartolomeo M, Raghav K, et al. The Lancet Oncology.
Zhou C, Ramalingam SS, Kim TM, et al. JAMA Oncology.
Khan SM, Emile SH, Choudhry MS, Sumbal R. Updates in Surgery.
US Preventive Services Task Force, Davidson KW, Barry MJ, et al. JAMA.
Basu P, Malvi SG, Joshi S, et al. Lancet Oncology.
Giannis D, Cerullo M, Moris D, et al. Cancers.
Carlson ML, Link MJ. New England Journal of Medicine.
Sartor O, de Bono J, Chi KN, et al. New England Journal of Medicine.
Soumerai JD, Mato AR, Dogan A, et al. The Lancet Haematology.
Pedersen KS, Foster NR, Overman MJ, et al. Clinical Cancer Research.
The history entries editors wrote on cancer records: the dated turning points of each disease.
Relapsed and refractory acute lymphoblastic leukaemia in children
Gallbladder cancer. Median overall survival 6.2 vs 5.3 months; one-year survival 25.9 vs 11.4 percent. NIFTY (liposomal irinotecan) published the same year.
Extrahepatic cholangiocarcinoma (perihilar and distal)
Group 3 and group 4 medulloblastoma (non-WNT/non-SHH)
Bladder & urothelial cancer
Muscle-invasive and advanced bladder cancer
EGFR-mutated non-small-cell lung cancer
Perivascular epithelioid cell tumour (PEComa)
Chronic myeloid leukaemia (CML). ASCEMBL vs bosutinib in third line.
Systemic mastocytosis. EXPLORER and PATHFINDER; FDA approval June 2021.
Advanced systemic mastocytosis (aggressive SM, SM with an associated haematological neoplasm, mast cell leukaemia)
Renal cell carcinoma
Clear cell renal cell carcinoma
Pancreatic neuroendocrine tumours
Hereditary pheochromocytoma and paraganglioma (SDHx, VHL, RET, NF1, MAX and TMEM127)
Spinal cord tumours (intramedullary and intradural)
Higher-risk myelodysplastic syndromes
Chordoma. Phase 2 of GI-6301 yeast-brachyury vaccine with radiation (NCT02383498).
Follicular lymphoma. Axicabtagene (ZUMA-5) approved; tisagenlecleucel (ELARA) 2022; lisocabtagene 2024.
HIV-associated (AIDS-related) lymphomas. Case series and the AMC-sponsored study show safety; trial eligibility broadened.
Locally advanced and metastatic basal cell carcinoma
Basal cell carcinoma
Basal cell carcinoma. Objective response in 26 of 84 patients (31 per cent) whose disease had progressed on or who could not tolerate a hedgehog inhibitor.
Oesophageal squamous cell carcinoma
Microsatellite-unstable (MSI-high) gastric cancer
Gastric & gastro-oesophageal junction cancer
PD-L1-high gastric cancer
Oesophageal cancer
Intrahepatic cholangiocarcinoma
Grade 3 well-differentiated neuroendocrine tumour
Mesothelioma
Oesophageal cancer
HER2-positive breast cancer
Mismatch repair deficient (MSI-high) pancreatic ductal adenocarcinoma
Mismatch-repair-deficient endometrial cancer
Melanoma
BRAF V600-mutant melanoma
Vascular tumours (angiosarcoma, epithelioid haemangioendothelioma, kaposiform haemangioendothelioma). Surveillance first, sirolimus for progression (ESMO Open).
Locally advanced cervical cancer
PD-L1-high non-small-cell lung cancer without a driver mutation
POLE-ultramutated endometrial cancer
Pancreatoblastoma
HER2-positive gastric cancer
Vulvar cancer
HPV-independent vulvar squamous cell carcinoma (p53-mutant)
Vulvar cancer
HPV-associated vulvar squamous cell carcinoma
Early-stage classical Hodgkin lymphoma (stage I to II)
Triple-negative breast cancer (TNBC). Schettini (3,689 HER2-negative cancers, 36.6% of triple-negative) and Denkert (34.0% of 1,162 hormone receptor-negative trial patients) fix th...
Relapsed or refractory multiple myeloma
Multiple myeloma
Multiple myeloma
Prostate cancer. KEYNOTE-199 gave objective response rates of 5 and 3 percent with pembrolizumab and PD-L1 predicted nothing, consistent with a median tumour mutational burden of 2...
Peritoneal mesothelioma. Early phase 2 and retrospective data for nivolumab plus ipilimumab and for atezolizumab plus bevacizumab.
Metastatic triple-negative breast cancer
Resectable stage I to III non-small-cell lung cancer
Plasma cell leukaemia
NUT carcinoma (midline carcinoma with NUTM1 rearrangement). Chau and colleagues, JCO: fusion partner and initial treatment predict survival.
Biliary tract cancer (cholangiocarcinoma)
Recurrent and metastatic nasopharyngeal carcinoma
Nasopharyngeal carcinoma
Head and neck squamous cell carcinoma
Relapsed and refractory classical Hodgkin lymphoma
Triple-negative breast cancer (TNBC). Neoadjuvant/adjuvant pembrolizumab approved for stage II-III TNBC; OS benefit confirmed 2024.
Stage IIB and IIC melanoma
Endometrial cancer
Endometrial cancer with no specific molecular profile
Advanced or recurrent endometrial cancer
Vaginal squamous cell carcinoma (HPV-associated)
Cervical cancer
Recurrent or metastatic cervical cancer
Thymic carcinoma
Diffuse large B-cell lymphoma
Polycythaemia vera (PV). Ropeginterferon plus phlebotomy kept more low-risk patients at target than phlebotomy alone.
Non-small-cell lung cancer. Whole genomes of 232 never-smoker lung cancers find no tobacco signature and three copy-number subtypes, one of them slow-growing with driver progenitor...
Locoregionally advanced nasopharyngeal carcinoma (stage III to IVA)
Goblet cell adenocarcinoma of the appendix
HR-positive / HER2-negative breast cancer
Gastric & gastro-oesophageal junction cancer
Cancer of unknown primary, unfavourable (adenocarcinoma and poorly differentiated carcinoma)
Cancer of unknown primary (CUP)
Renal cell carcinoma
HPV-positive oropharyngeal cancer
Chronic myeloid leukaemia, accelerated and blast phase
Triple-negative breast cancer (TNBC). One year of olaparib after standard therapy improves iDFS and OS in gBRCA carriers.
Male breast cancer. Trial included men.
Locally advanced cervical cancer
Papillary renal cell carcinoma
Triple-negative breast cancer (TNBC). Rugo and colleagues on 614 IMpassion130 tumours: SP142, SP263 and 22C3 positive in 46, 75 and 73 percent, concordance 69 percent.
Metastatic hormone-sensitive prostate cancer
Early triple-negative breast cancer
Inflammatory breast cancer
Prostate cancer. Circulating tumour DNA is detectable in 94% of 3,334 men with advanced prostate cancer and agrees with tissue on BRCA mutations 93% of the time; in parallel, clona...
Rectal cancer
Colorectal cancer. Adding oxaliplatin hyperthermic intraperitoneal chemotherapy to complete cytoreductive surgery changed nothing (median overall survival 41.7 against 41.2 months...
Undifferentiated carcinoma of the pancreas with osteoclast-like giant cells
Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma). Confirmatory Ro-CHOP trial negative.
Myeloproliferative neoplasms (PV, ET, myelofibrosis). PROUD/CONTINUATION-PV: superior long-term haematologic and molecular response versus hydroxyurea.
BRCA or PALB2-mutant pancreatic ductal adenocarcinoma
Epithelioid haemangioendothelioma
Small-cell lung cancer
Lung cancer (all types). The United States task force lowered eligibility to age 50 and 20 pack-years, two years after Aldrich showed 31 percent of white smokers qualified against...
Medulloblastoma
KRAS G12C-mutant non-small-cell lung cancer
KRAS G12C-mutant pancreatic ductal adenocarcinoma
KRAS G12C-mutant colorectal cancer
Pancreatic ductal adenocarcinoma. Only 1-2% of pancreatic cancers carry G12C, but the door is open.
Non-small-cell lung cancer
Pancreatic ductal adenocarcinoma. Reactive and deserted tissue states track immunity and chemoprotection; CA 19-9 rises two years before diagnosis, reaching 60% sensitivity only in...
Uveal melanoma
MET exon 14 and MET-amplified non-small-cell lung cancer
Recurrent or metastatic cervical cancer
Cervical cancer
Colorectal cancer. RAPIDO cuts three-year treatment failure from 30.4 to 23.7 percent; PRODIGE 23 raises three-year disease-free survival from 69 to 76 percent.
Ovarian cancer
Early-onset colorectal cancer (under 50)
Hairy cell leukaemia
Prostate cancer
Metastatic castration-resistant prostate cancer
PDGFRA D842V-mutant GIST
Meningioma
Ependymoma
Paediatric high-grade glioma (excluding diffuse midline glioma)
WNT-activated medulloblastoma
Group 3 and group 4 medulloblastoma (non-WNT/non-SHH)
Central nervous system germ cell tumours (germinoma and non-germinomatous)
Spinal cord tumours (intramedullary and intradural)
Astrocytoma, IDH-mutant (grades 2 to 4)
SHH-activated medulloblastoma
Glioma & glioblastoma
Lung cancer (all types). The 2021 WHO Classification of Thoracic Tumours added a chapter on classifying small diagnostic samples, graded invasive non-mucinous adenocarcinoma by gro...
Waldenström macroglobulinaemia. Fewer atrial fibrillation events than ibrutinib.
Marginal zone lymphoma
Advanced and metastatic small bowel adenocarcinoma
The since year on technology records: first use in humans or first approval, as the record states it.
First use in humans or first approval, as the technology record states it.
First use in humans or first approval, as the technology record states it.
First use in humans or first approval, as the technology record states it.
First use in humans or first approval, as the technology record states it.
First use in humans or first approval, as the technology record states it.
First use in humans or first approval, as the technology record states it.
First use in humans or first approval, as the technology record states it.
The founded year on company records.
Toronto
Cambridge, MA
Cambridge, MA
Watertown, MA
Wuxi, Jiangsu
Jersey City, NJ
San Diego, CA
Melbourne
Watertown, MA
Shanghai
San Diego, California
The funding rounds on company records, each with the source that states the figure.
$60m. Led by F-Prime Capital with OrbiMed, Deerfield Management, Decheng Capital and RA Capital Management; company launched June 2021 (formerly DNAMx).
$1.0bn. Upfront payment of approximately $1 billion plus up to $225 million in development milestones; agreement announced 21 December 2021
$63m. Equity offering, first sale 24 November 2021 (filed March 2024)
Debuted on the Warsaw Stock Exchange main market on 19 April 2021; amount raised not stated on the fetched pages
$40m. Led by Tiger Global Management
$127m. Form D filed 4 January 2021; first sale 17 December 2020; USD 127.2 million sold of a USD 167.2 million equity offering
$46m. Form D filed 9 November 2021; first sale 26 October 2021; USD 45.7 million sold of a USD 100 million equity offering at filing
$345m. 21,562,500 shares at 16 US dollars including full exercise of the underwriters' option; closed 20 July 2021
$68m. Co-led by Section 32 and Casdin Capital with Two Sigma Ventures, December 2021.
$41m. Total sold of a 51 million US dollar offering per Form D filed December 2021
$47m. Described by the company as a USD 47 million (about GBP 34 million) financing round co-led by Mirae Asset Capital, Celltrion and Premier Partners; series letter not stated
$390m. $390 million in cash for the remaining equity after a $25 million minority investment in May 2020; completion announced 18 June 2021.
$223m. Shares priced at $17.00 including full option exercise; Nasdaq JANX from 11 June 2021
$30m. Co-led by F-Prime Capital and Atlas Venture with Eight Roads Ventures
$50m. Total sold per Form D filed February 2021
$30m. Total sold per amended Form D filed August 2021
Led by Elaia Partners; amount not stated in the fetched release copy
$103m. BioSpace copy of the Business Wire release dated 15 December 2021
$55m. Round name not given in the release; $55 million led by RA Capital Management, April 2021.
$84m. Includes a previously announced USD 30 million tranche; led by IMM Investment
$12m. Led by Northpond Ventures
$63m. Led by founding investor Versant Ventures; announced June 2021
$52m
$353m. Nasdaq listing via merger with BCTG Acquisition Corp; approximately 353 million US dollars expected gross proceeds (about 167 million in trust plus a 186 million PIPE led by...
$212m. Total sold per Form D filed April 2021
$199m. 12.42 million shares at 16 US dollars including full exercise of the underwriters' option; closed 17 September 2021
The founded year on journal records.
American Association for Cancer Research
Elsevier
The selected publications each biography lists, which is a reading of that person rather than a reading of the year.
JNCI
Lancet
Lancet Oncology
NEJM
Lancet
Lancet
Gynecologic Oncology
JACC Clin Electrophysiol
JCO
Scientific Reports
Lancet
NEJM
NEJM
New England Journal of Medicine
NEJM
New England Journal of Medicine
Journal of Clinical Oncology
Journal of Clinical Oncology
ESMO Open
Kidney International
Nature
Blood Advances
Pharmaceutics
JNCI
Endocrine-Related Cancer
Lancet
PLOS ONE
Lancet Oncology
Lancet Oncology
JAMA Oncol
Lancet Oncology
Clinical Lung Cancer
Lancet
Frontiers in Oncology
Annals of Oncology
British Journal of Surgery
Gynecologic Oncology
The Breast Journal
The Breast
Blood
Cancer Discovery
Blood Advances
Nature
Journal for ImmunoTherapy of Cancer
Gastroenterology
European Urology
Nature Biomedical Engineering
BJU International
European Journal of Cancer
ESMO Open
The Lancet Oncology
NEJM
Journal of Clinical Oncology
Cancer Cell
Biomolecules
Journal of Clinical Oncology
JAMA Network Open
Liver Cancer
JAMA Oncology
International Journal of Gynecological Cancer
Radiotherapy and Oncology
Annals of Oncology
Lancet
Seminars in Cancer Biology
Kidney International
Cancer Treatment Reviews
Cancer Discovery
Breast Cancer Research and Treatment
Clinical Cancer Research
Lancet
Lancet
JCO
Journal of Thoracic Oncology
Nature Reviews Cancer
European Journal of Cancer
Journal of Clinical Oncology
Gynecologic Oncology
Journal of Clinical Oncology
Cardiovasc Toxicol
Science
Annual Review of Cancer Biology
The Lancet Oncology
JCO
NEJM
Frontiers in Immunology
The Lancet Haematology
Bulletin du Cancer
Cancer Discovery
Int J Mol Sci
Nature Reviews Clinical Oncology
Gastric Cancer
Translational Oncology
JAMA Surg
NEJM
Journal of Clinical Oncology
Clinical Cancer Research
European Journal of Surgical Oncology
Cancer Science
Journal of Experimental & Clinical Cancer Research
Lancet Regional Health Europe
NEJM
New England Journal of Medicine
Nature Reviews Cancer
Journal of Clinical Oncology
Radiother Oncol
Cell
Cancers
Mol Ther Oncolytics
Journal of Clinical Medicine
Molecular Cancer
Nature Medicine
Nature Medicine
Journal of Clinical Oncology
Journal of Clinical Oncology
Lancet Oncology
Journal of Biomedical Science
Clinical and Molecular Hepatology
The Lancet Respiratory Medicine
Clinical Cancer Research
JCO
Lancet
NEJM
JCO
mSphere
Molecular Cancer Therapeutics
Bulletin du Cancer
NEJM
Journal of Clinical Oncology
Lancet Oncology
Lancet
Journal of Clinical Oncology
Lancet Oncology
Annals of Oncology
Lancet Oncology
The Lancet Oncology
J Clin Oncol
Viruses
Breast Cancer: Targets and Therapy
Clinical Cancer Research
Journal of Nuclear Medicine
Nat Rev Dis Primers
Journal of Cancer Research and Therapeutics
Lancet Oncology
Clinical Cancer Research
New England Journal of Medicine
NEJM
JCO
Clinical and Translational Science
BMJ
Journal of Urology
Journal of Urology
HPB
Cell Proliferation
NEJM
JAMA Oncology
The Lancet
Cancer Science
Blood Cancer Journal
Scientific Reports
Lancet Oncology
Annals of Oncology
Cell
JAMA Oncology
Journal of the National Comprehensive Cancer Network
NEJM
Nature Communications
Lancet Oncology
Journal for ImmunoTherapy of Cancer
Neuro-Oncology
European Urology
Cancer Communications
Lancet
Breast Cancer Research and Treatment
Lancet
The Lancet Oncology
Journal of Experimental & Clinical Cancer Research
Nature
Genes & Diseases
Breast Cancer Research and Treatment
Acta Clin Croat
Nuclear Medicine Communications
JAMA Oncology
Cancer Epidemiol
Radiotherapy and Oncology
JAMA Oncology
Cancer Discovery
Science Translational Medicine
Clinical Cancer Research
Cancer
Journal of Geriatric Oncology
Journal of Clinical Medicine
Cancer Research
JAMA Oncology
Clinical Cancer Research